H. Lundbeck A/S: Comprehensive Deep Dive Research Report
Investor-Grade Analysis with Ada Patient Finder Assessment
Report Date: March 11, 2026 | Prepared by: Ada Cockpit
FORWARD-LOOKING DISCLAIMER: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section.
Executive Summary
Revenue (FY 2025)
DKK 24.6B
+13% CER
EBITDA Margin
32.0%
Adjusted
Net Income
DKK 3.2B
+2%
Employees
5,268
As of Dec 31, 2025
H. Lundbeck A/S is a Danish pharmaceutical company specializing in neuroscience and brain diseases. Founded in 1915 and headquartered in Valby, Copenhagen, Lundbeck has evolved into a pure-play neuroscience leader focusing on migraine, depression, schizophrenia, Alzheimer's agitation, epilepsy, and neurodegeneration.
Lundbeck delivered record 2025 performance with revenue of DKK 24,630 million (+13% CER) and adjusted EBITDA of DKK 7,881 million (32.0% margin). Strategic brands (Vyepti and Rexulti) drove 77% of revenue (DKK 19,011M), growing 19% year-over-year. The United States represents 54% of revenue (+21% CER).
CEO Charl van Zyl (joined September 2023) executes a "Focused Innovator" strategy targeting neuro-rare and neuro-specialty diseases, with four Phase 3 programs in 2026 and the recent $2.6 billion Longboard acquisition securing bexicaserin for epileptic encephalopathies.
Strong growth acceleration 2023-2025 driven by strategic brands
Key Financial Metrics (FY 2025)
Metric
FY 2025
FY 2024
Change
Revenue
DKK 24,630M
DKK 22,004M
+12% (+13% CER)
EBITDA
DKK 7,140M
DKK 5,146M
+39%
Adjusted EBITDA
DKK 7,881M
DKK 6,352M
+24% CER
EBITDA Margin
29.0%
23.4%
+5.6pp
Adjusted EBITDA Margin
32.0%
28.8%
+3.2pp
Net Income
DKK 3,192M
DKK 3,143M
+2%
Net Debt/EBITDA
1.2x
2.4x
Improved
Top Products by Revenue (FY 2025)
Product
Indication(s)
Revenue (FY 2025)
Growth (CER)
Vyepti (eptinezumab)
Migraine prevention
~DKK 5,745M
+23%
Rexulti (brexpiprazole)
Schizophrenia, MDD adjunct, AADAD
~DKK 6,300-6,500M (est.)
+26% (9M)
Abilify LAI Franchise
Schizophrenia, Bipolar I
DKK 3,776M
+10%
Trintellix/Brintellix
Major Depressive Disorder
DKK 3,453M (9M 2025)
-1% (9M)
Cipralex/Lexapro
Depression, Anxiety
DKK 1,573M (9M 2025)
0% (9M)
R&D Pipeline: Phase 3 and Late-Stage Programs
Program
Mechanism
Indication
Phase
Expected Readout
Amlenetug
Anti-alpha-synuclein mAb
Multiple System Atrophy (MSA)
Phase 3 (MASCOT)
2026-2027
Bexicaserin
5-HT2C receptor agonist
Dev. & Epileptic Encephalopathies
Phase 3 (DEEp)
Target launch late 2028
Lu AG09222
Anti-PACAP mAb
Migraine prevention
Phase 2b (PROCEED)
Phase 3 entry 2026
Lu AG13909
ACTH blocker mAb
Cushing's, CAH
Phase 1b/2
Not specified
Geographic Revenue Split (FY 2025)
Geography
Revenue (DKK Million)
% of Total
Growth (CER)
United States
13,287
54%
+21%
Europe
~5,600 (estimated/derived)
~23%
+1% (9M)
International Operations
~5,743 (estimated/derived)
~23%
0% (9M)
Ada Patient Finder Top Opportunities
1. Vyepti (Migraine Prevention) - Fit Score: 9/10
Net Revenue Per Patient: $14,400/year (U.S., after rebates) | Finder's Fee: $1,150-1,730
Chronic migraine affects 15-18 million people in major markets, yet 50-55% remain undiagnosed, often waiting 5+ years from symptom onset to proper diagnosis. These patients suffer an average of 20 headache days per month, incurring 1.89x higher healthcare utilization (ER visits, neurologist referrals) compared to correctly diagnosed patients, while their condition is misattributed to tension headaches or sinus issues. Ada Patient Finder's clinical-grade symptom assessment can identify these undiagnosed patients at scale, surfacing the characteristic pattern of recurrent moderate-to-severe headache with photophobia, nausea, and functional disability that defines migraine. With Vyepti generating $14,400 net revenue per patient annually and 75.7% of patients who failed prior CGRPs improving on Vyepti (INFUSE study), Ada Patient Finder represents a high-value market expansion tool. At 8-12% of first-year revenue, the finder's fee ($1,150-2,040 per patient found and treated) is economically compelling for Lundbeck.
2. Bexicaserin (DEEs) - Fit Score: 8/10
Net Revenue Per Patient (Projected): $72,000-108,000/year (U.S.) | Finder's Fee: $5,760-12,960
Developmental and Epileptic Encephalopathies (DEEs), including Dravet and Lennox-Gastaut syndromes, affect ~220,000 people in the U.S., with half (110,000) lacking approved therapies. Yet 30-50% of epilepsy patients are misdiagnosed or underdiagnosed, facing an average diagnostic delay of 1-5 years from first seizure to correct DEE diagnosis, as early seizures are often misattributed to febrile seizures or "just epilepsy." Ada Patient Finder's pediatric-focused symptom assessment can identify these undiagnosed DEE cases by surfacing the distinctive pattern of multiple seizure types (tonic-clonic, absence, myoclonic), developmental delay, and medication resistance. With bexicaserin projected to generate $72,000-108,000 net revenue per patient annually (U.S.) and targeting peak sales of $1.5-2.0 billion, Ada Patient Finder represents a high-value market expansion tool for Lundbeck's neuro-rare franchise. At 8-12% of first-year revenue, the finder's fee ($5,760-12,960 per patient) is economically compelling.
Strong balance sheet (net debt/EBITDA 1.2x) and cash generation support M&A optionality.
Neuro-rare focus aligns with favorable pricing environment and orphan drug pathways.
Bearish Factors
Generic cliffs loom for Abilify Maintena (mid-2020s), Trintellix (timeline unclear).
2026 guidance reflects moderation (5-8% revenue growth vs. 13% in 2025) due to FX, R&D, and generic headwinds.
Competitive intensity in migraine (oral gepants), psychiatry (KarXT), and AADAD (Nuplazid).
Pipeline execution risk: Four Phase 3 programs introduce binary outcomes.
Patent/Exclusivity Summary
Product
Indication
US Exclusivity
EU Exclusivity
Key Risk
Vyepti
Migraine prevention
Composition of matter: Q2 2034; franchise: Q3 2037
Similar to U.S.
Biosimilar development post-2034
Rexulti
Schizophrenia, MDD, AADAD
Not specified; est. late 2020s
Not specified
Patent timeline unclear
Abilify Maintena
Schizophrenia, Bipolar I
1-month: March 2034; 2-month: mid-2030s
Similar to U.S.
Generic entry mid-2020s some markets
Trintellix/Brintellix
MDD
Not specified
Not specified
U.S. promotional cessation 2025 signals prep for generic
References and Sources
This report draws on 46+ sources including Lundbeck investor materials, earnings transcripts, regulatory filings, peer-reviewed literature, and industry reports. Key sources: